Abstract 2099: Model-driven optimization of anti-angiogenics combined with chemotherapy: application to bevacizumab + pemetrexed/cisplatin doublet in NSCLC-bearing mice - Inria - Institut national de recherche en sciences et technologies du numérique
Communication Dans Un Congrès Année : 2016

Abstract 2099: Model-driven optimization of anti-angiogenics combined with chemotherapy: application to bevacizumab + pemetrexed/cisplatin doublet in NSCLC-bearing mice

Domaines

Cancer

Sebastien Benzekry  : Connectez-vous pour contacter le contributeur

https://inria.hal.science/hal-01404637

Soumis le : mardi 29 novembre 2016-09:46:08

Dernière modification le : mercredi 13 novembre 2024-11:00:02

Fichier non déposé

Dates et versions

hal-01404637 , version 1 (29-11-2016)

Identifiants

Citer

Joseph Ciccolini, Sebastien Benzekry, Sarah Giacometti, Fabrice Barlesi, Dominique Barbolosi. Abstract 2099: Model-driven optimization of anti-angiogenics combined with chemotherapy: application to bevacizumab + pemetrexed/cisplatin doublet in NSCLC-bearing mice. 107th Annual Meeting of the American Association for Cancer Research, 2016, New Orleans, France. pp.20, ⟨10.1158/1538-7445.AM2016-2099⟩. ⟨hal-01404637⟩

Exporter

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

CNRS INRIA UNIV-AMU IMB INSMI INRIA2
154 Consultations
0 Téléchargements

Altmetric

Partager

More